Skip to content
COVID-19 / SPECIALTY RESEARCH

Vascular MedicineIn perspective.

The key COVID-19 findings in vascular medicine, distilled into a clear, readable brief. The evidence is here whenever you want to go deeper.

INSIDE THIS MONITOR
41cited sources
7available findings

Study findings updated

AI-assisted evidence summary. For general information. These findings are not individual medical advice or a clinician endorsement.

THE SHORT VERSION

What’s worth knowing.

The key findings, what they mean, and the context that matters.

THE HEADLINE TAKEAWAY48.8% vs 33.4%; risk difference 15.4%

Death or cardiovascular hospitalization was more common after COVID-19 than influenza

Among US Medicare beneficiaries aged 65 or older, death from any cause or hospitalization for specified heart and circulation problems within 1 year occurred in 48.8% after Omicron-era COVID-19 hospitalization versus 33.4% after historical 2017-2018 influenza hospitalization.

The combined outcome included death from any cause or hospitalization for heart attack, ischemic stroke, transient ischemic attack, blood clots in the lungs or deep veins, heart failure or cardiac arrest. The influenza group was historical; other design details are not recorded in this summary.

See the evidence

Within 1 year, composite risk of all-cause death or hospitalization for myocardial infarction, ischemic stroke, transient ischemic attack, pulmonary embolism, deep vein thrombosis, heart failure, or cardiac arrest among Medicare beneficiaries aged ≥65 hospitalized with Omicron-era COVID-19 versus a historical 2017-2018 influenza hospitalization cohort.

48.8% vs 33.4%; risk difference 15.4%
95% CI: 15.1%-15.6%

Decker, Sérgio R R et al.. Long-term Cardiovascular Outcomes in US Medicare Beneficiaries After COVID-19 Hospitalization During the Omicron Era.. Circulation. Population health and outcomes. 2026.

Added

02

The Long COVID vascular finding largely reflected elevated blood pressure

76%higher relative odds

Long COVID cases had 76% higher adjusted odds of an abnormal result on the study's blood vessel assessment than controls. The result largely reflected elevated blood pressure.

This population-based case-control study reports an association. An analysis limited to Long COVID cases reporting fatigue also found higher adjusted odds, but its reference group is not named. No timeframe or absolute risks are recorded in this summary.

See the evidence

76% higher relative odds, calculated from OR 1.76. This is not an absolute percentage-point difference.

Multivariable-adjusted odds of a vascular-domain deficit, largely attributable to elevated blood pressure, among long COVID cases versus controls

OR 1.76
95% CI: 1.04-2.97

Fernández-Sanlés, Alba et al.. Multi-organ structural and functional deficits in association with long COVID: a population-based case-control study.. EClinicalMedicine. 2026.

Added

Multivariable-adjusted odds of a vascular-domain deficit, largely attributable to elevated blood pressure, when long COVID cases were restricted to those reporting fatigue

OR 3.04
95% CI: 1.36-6.80

Fernández-Sanlés, Alba et al.. Multi-organ structural and functional deficits in association with long COVID: a population-based case-control study.. EClinicalMedicine. 2026.

Added

Study-specific findings. Different populations, treatments and follow-up periods can produce different results.

THE RESEARCH, AS IT ARRIVES

Latest studies.

The newest findings added to this collection.
The learning from each, already distilled.

  1. STUDY 01Findings added
    TL;DR

    The Long COVID vascular finding largely reflected elevated blood pressure

    76%higher relative odds

    Long COVID cases had 76% higher adjusted odds of an abnormal result on the study's blood vessel assessment than controls. The result largely reflected elevated blood pressure.

    This population-based case-control study reports an association. An analysis limited to Long COVID cases reporting fatigue also found higher adjusted odds, but its reference group is not named. No timeframe or absolute risks are recorded in this summary.

    Study details & original results

    Fernández-Sanlés, Alba et al.. Multi-organ structural and functional deficits in association with long COVID: a population-based case-control study.. EClinicalMedicine. 2026.

    Multivariable-adjusted odds of a vascular-domain deficit, largely attributable to elevated blood pressure, among long COVID cases versus controls

    OR 1.76
    95% CI: 1.04-2.97

    Multivariable-adjusted odds of a vascular-domain deficit, largely attributable to elevated blood pressure, when long COVID cases were restricted to those reporting fatigue

    OR 3.04
    95% CI: 1.36-6.80

    76% higher relative odds, calculated from OR 1.76. This is not an absolute percentage-point difference.

    Citation in Vascular Medicine
  2. STUDY 02Findings added
    TL;DR

    Death or cardiovascular hospitalization was more common after COVID-19 than influenza

    48.8% vs 33.4%; risk difference 15.4%

    Among US Medicare beneficiaries aged 65 or older, death from any cause or hospitalization for specified heart and circulation problems within 1 year occurred in 48.8% after Omicron-era COVID-19 hospitalization versus 33.4% after historical 2017-2018 influenza hospitalization.

    The combined outcome included death from any cause or hospitalization for heart attack, ischemic stroke, transient ischemic attack, blood clots in the lungs or deep veins, heart failure or cardiac arrest. The influenza group was historical; other design details are not recorded in this summary.

    Study details & original results

    Decker, Sérgio R R et al.. Long-term Cardiovascular Outcomes in US Medicare Beneficiaries After COVID-19 Hospitalization During the Omicron Era.. Circulation. Population health and outcomes. 2026.

    Within 1 year, composite risk of all-cause death or hospitalization for myocardial infarction, ischemic stroke, transient ischemic attack, pulmonary embolism, deep vein thrombosis, heart failure, or cardiac arrest among Medicare beneficiaries aged ≥65 hospitalized with Omicron-era COVID-19 versus a historical 2017-2018 influenza hospitalization cohort.

    48.8% vs 33.4%; risk difference 15.4%
    95% CI: 15.1%-15.6%

    Citation in Vascular Medicine
2 of 2 study updates

Dates show when findings were added here, not when papers were published. Study populations and comparisons differ.

WHEN YOU WANT TO GO DEEPER
See all 7 findingsOriginal results, comparisons and study details.
4 of 4 source groupsFindings stay together with their study.
SOURCE 412 findings

Fernández-Sanlés, Alba et al.. Multi-organ structural and functional deficits in association with long COVID: a population-based case-control study.. EClinicalMedicine. 2026.

Multivariable-adjusted odds of a vascular-domain deficit, largely attributable to elevated blood pressure, among long COVID cases versus controls

Added
OR 1.7695% CI: 1.04-2.97Source [41]

Multivariable-adjusted odds of a vascular-domain deficit, largely attributable to elevated blood pressure, when long COVID cases were restricted to those reporting fatigue

Added
OR 3.0495% CI: 1.36-6.80Source [41]
SOURCE 401 finding

Decker, Sérgio R R et al.. Long-term Cardiovascular Outcomes in US Medicare Beneficiaries After COVID-19 Hospitalization During the Omicron Era.. Circulation. Population health and outcomes. 2026.

Within 1 year, composite risk of all-cause death or hospitalization for myocardial infarction, ischemic stroke, transient ischemic attack, pulmonary embolism, deep vein thrombosis, heart failure, or cardiac arrest among Medicare beneficiaries aged ≥65 hospitalized with Omicron-era COVID-19 versus a historical 2017-2018 influenza hospitalization cohort.

Added
48.8% vs 33.4%; risk difference 15.4%95% CI: 15.1%-15.6%Source [40]
SOURCE 013 findings

Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nature Medicine. 2022;28(3):583-590.

Peripheral Artery Disease

+74%HR 1.74 (95% CI: 1.58-1.92)Source [1]

Deep Vein Thrombosis

+113%HR 2.13 (95% CI: 1.89-2.40)Source [1]
All 3 findings from this source

Pulmonary Embolism

+193%HR 2.93 (95% CI: 2.53-3.39)Source [1]
SOURCE 021 finding

Nagele MP, Haubner B, Tanner FC, Ruschitzka F, Flammer AJ. Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. Atherosclerosis. 2020;314:58-62.

Endothelial Dysfunction

40-60%FMD reduction in acute COVID-19Source [2]
Browse the 41 original sourcesThe complete bibliography behind this monitor.
  1. [1]

    Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nature Medicine. 2022;28(3):583-590.

    Open original source in a new tab
  2. [2]

    Nagele MP, Haubner B, Tanner FC, Ruschitzka F, Flammer AJ. Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. Atherosclerosis. 2020;314:58-62.

    Open original source in a new tab
  3. [3]

    Al-Aly Z, Bowe B, Xie Y. Outcomes of SARS-CoV-2 Reinfection. Nature Medicine. 2022;28(11):2398-2405.

    Open original source in a new tab
  4. [4]

    Taquet M, Dercon Q, Harrison PJ. Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. Brain Behav Immun. 2022;103:154-162.

    Open original source in a new tab
  5. [5]

    Ramacciotti E, Barile Agati L, Calderaro D, et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE). Lancet. 2022;399(10319):50-59.

    Open original source in a new tab
  6. [6]

    Szeghy RE, Province VM, Gideon DM, et al. Endothelial dysfunction is associated with post-acute COVID-19 syndrome: A systematic review and meta-analysis. Vasc Med. 2022;27(3):289-297.

    Open original source in a new tab
  7. [7]

    Haffke M, Freitag H, Rudolf G, et al. Endothelial dysfunction and altered endothelial biomarkers in patients with post-COVID-19 syndrome and chronic fatigue syndrome (ME/CFS). J Transl Med. 2022;20(1):138.

    Open original source in a new tab
  8. [8]

    Chioh FW, Fong SW, Young BE, et al. Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation. Elife. 2021;10:e64909.

    Open original source in a new tab
  9. [9]

    Stahl K, Gronski PA, Kiber Y, et al. Injury to the endothelial glycocalyx in critically ill patients with COVID-19. Am J Respir Crit Care Med. 2020;202(8):1178-1181.

    Open original source in a new tab
  10. [10]

    Ratchford SM, Stickford JL, Province VM, et al. Vascular alterations among young adults with SARS-CoV-2. Am J Physiol Heart Circ Physiol. 2021;320(1):H404-H410.

    Open original source in a new tab
  11. [11]

    Bruno RM, Spronck B, Hametner B, et al. Covid-19 effects on ARTErial StIffness and vascular ageiNg: CARTESIAN study rationale and protocol. Artery Res. 2021;27(2):59-66.

    Open original source in a new tab
  12. [12]

    Tudoran C, Tudoran M, Lazureanu VE, et al. Evidence of pulmonary arterial hypertension after SARS-CoV-2 infection in subjects without previous significant cardiovascular pathology. J Clin Med. 2021;10(2):199.

    Open original source in a new tab
  13. [13]

    Malas MB, Naazie IN, Elsayed N, et al. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicine. 2020;29:100639.

    Open original source in a new tab
  14. [14]

    Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in hospitalized patients with COVID-19 in a New York City health system. JAMA. 2020;324(8):799-801.

    Open original source in a new tab
  15. [15]

    Osiaevi I, Schulze A, Setani K, et al. Persistent capillary rarefication in long COVID syndrome. Angiogenesis. 2023;26(1):53-61.

    Open original source in a new tab
  16. [16]

    Charfeddine S, Ibn Hadj Amor H, Jdidi J, et al. Long COVID 19 syndrome: Is it related to microcirculation and endothelial dysfunction? Insights from TUN-EndCOV study. Front Cardiovasc Med. 2021;8:745758.

    Open original source in a new tab
  17. [17]

    Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120-128.

    Open original source in a new tab
  18. [18]

    Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417-1418.

    Open original source in a new tab
  19. [19]

    Goshua G, Pine AB, Meizlish ML, et al. Endotheliopathy in COVID-19-associated coagulopathy: Evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020;7(8):e575-e582.

    Open original source in a new tab
  20. [20]

    Goldman IA, Ye K, Scheinfeld MH. Lower-extremity arterial thrombosis associated with COVID-19 is characterized by greater thrombus burden and increased rate of amputation and death. Radiology. 2020;297(2):E263-E269.

    Open original source in a new tab
  21. [21]

    Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: Major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146.

    Open original source in a new tab
  22. [22]

    REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021;385(9):777-789.

    Open original source in a new tab
  23. [23]

    Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST Guideline and Expert Panel Report. Chest. 2020;158(3):1143-1163.

    Open original source in a new tab
  24. [24]

    Al-Aly Z, Bowe B, Xie Y. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259-264.

    Open original source in a new tab
  25. [25]

    Ambrosino P, Calcaterra IL, Mosella M, et al. Endothelial dysfunction in COVID-19: A systematic review and meta-analysis. Biomedicines. 2022;10(4):812.

    Open original source in a new tab
  26. [26]

    Rovas A, Osiaevi I, Busber K, et al. Microvascular dysfunction in COVID-19: The MYSTIC study. Angiogenesis. 2021;24(1):145-157.

    Open original source in a new tab
  27. [27]

    Invernizzi A, Torre A, Parrulli S, et al. Retinal findings in patients with COVID-19: Results from the SERPICO-19 study. EClinicalMedicine. 2020;27:100550.

    Open original source in a new tab
  28. [28]

    Pine AB, Meizlish ML, Goshua G, et al. Circulating markers of angiogenesis and endotheliopathy in COVID-19. Pulm Circ. 2020;10(4):2045894020966547.

    Open original source in a new tab
  29. [29]

    Schnaubelt S, Jirak P, Giannitsis E, et al. Comprehensive assessment of arterial stiffness and hemodynamic parameters in COVID-19 patients. J Am Heart Assoc. 2021;10(16):e022068.

    Open original source in a new tab
  30. [30]

    Townsend L, Fogarty H, Dyer A, et al. Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. J Thromb Haemost. 2021;19(4):1064-1070.

    Open original source in a new tab
  31. [31]

    Chi G, Lee JJ, Jamber A, et al. Venous thromboembolism among hospitalized patients with COVID-19 undergoing thromboprophylaxis: A systematic review and meta-analysis. J Clin Med. 2020;9(8):2489.

    Open original source in a new tab
  32. [32]

    Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. Res Pract Thromb Haemost. 2020;4(7):1178-1191.

    Open original source in a new tab
  33. [33]

    Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145-147.

    Open original source in a new tab
  34. [34]

    ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med. 2021;385(9):790-802.

    Open original source in a new tab
  35. [35]

    Connors JM, Brooks MM, Sciurba FC, et al. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: The ACTIV-4B randomized clinical trial. JAMA. 2021;326(17):1703-1712.

    Open original source in a new tab
  36. [36]

    Spyropoulos AC, Connors JM, Douketis JD, et al. Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1859-1865.

    Open original source in a new tab
  37. [37]

    Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020;75(23):2950-2973.

    Open original source in a new tab
  38. [38]

    Maccio U, Zinkernagel AS, Shambat SM, et al. SARS-CoV-2 leads to a small vessel endotheliitis in the heart. EBioMedicine. 2021;63:103182.

    Open original source in a new tab
  39. [39]

    Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: A two-centre descriptive study. Lancet Infect Dis. 2020;20(10):1135-1140.

    Open original source in a new tab
  40. [40]

    Decker, Sérgio R R et al.. Long-term Cardiovascular Outcomes in US Medicare Beneficiaries After COVID-19 Hospitalization During the Omicron Era.. Circulation. Population health and outcomes. 2026.

    Open original source in a new tab
  41. [41]

    Fernández-Sanlés, Alba et al.. Multi-organ structural and functional deficits in association with long COVID: a population-based case-control study.. EClinicalMedicine. 2026.

    Open original source in a new tab
ABOUT THIS MONITOR

Understanding includes the limits.

This is an AI-assisted evidence summary, not a clinician endorsement. Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results.

Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed. Personal health and treatment decisions belong in a conversation with a qualified clinician.

KEEP YOUR QUESTIONS CLOSE

A little more understanding.
Wherever you are.

Explore the ModernDoc app